Edwards Lifesciences Corporation (NYSE:EW) remains a hot topic within the investor community. Notably owned by 88% institutional investors, its stocks experienced various transactions lately. Several organizations, including Tobam and State of Alaska Department of Revenue, have cut their shares. Consecutively, Exane Asset Management has made a new investment worth $585,000, and GDS Wealth Management and Heck Capital Advisors LLC have acquired more shares.
Amid these shifts, Edwards Lifesciences will be hosting an ER conference on February 11, 2025. However, the officers and directors of the company are being probed by Former Louisiana Attorney General. Despite shareholders being in the red for the last three years, their underlying earnings have actually grown. Nevertheless, its stock has garnered a consensus rating of 'Hold' from analysts.
Edwards Lifesciences is also facing some legal issues as it has been sued for securities fraud, and it has a shareholder class action pending. Even then, the Q3 2024 results showed robust growth in TMTT sales, with further expected growth in Q3 earnings. However, predictions of a decline in earnings are also circulating.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 08 Feb 2025 13:20:26 GMT - Rating -3 - Innovation 0 - Information 7 - Rumor -5
